omeprazole has been researched along with alendronate in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (25.00) | 18.2507 |
2000's | 4 (33.33) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Mochizuki, T; Nemoto, R; Okabe, K; Satou, S | 1 |
Hussar, DA | 1 |
Girelli, CM; Reguzzoni, G; Rocca, F | 1 |
Beergabel, M; Gottesfeld, F; Keter, D; Lurie, Y; Malnick, SD; Walpart, A | 1 |
Arbak, S; Dülger, GA; Ersoy, Y; Goren, FO; Sener, G; Ulusoy, NB | 1 |
Bodde, EW; Jansen, JA; Kowalski, RS; Spauwen, PH | 1 |
Cottrell, JA; Gundlapalli, R; Kapadia, R; O'Connor, JP; Schachter, D; Vales, FM; Wadsworth, S | 1 |
Brandt, NJ; Stefanacci, RG | 1 |
Cegieła, U; Folwarczna, J; Nowińska, B; Pytlik, M | 1 |
2 review(s) available for omeprazole and alendronate
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Alendronate-induced esophagitis. A report of 2 cases].
Topics: Alendronate; Esophagitis; Female; Humans; Middle Aged; Omeprazole; Osteoporosis, Postmenopausal; Sucralfate; Time Factors | 1997 |
10 other study(ies) available for omeprazole and alendronate
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Response of MBT-2 bladder carcinoma-induced osteolysis to various agents.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcitonin; Cyclosporine; Diphosphonates; Female; Mice; Mice, Inbred C3H; Mice, Nude; Neoplasm Transplantation; Omeprazole; Osteoclasts; Osteolysis; Urinary Bladder Neoplasms | 1992 |
New therapeutic agents marketed in 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acarbose; Alendronate; Anti-Inflammatory Agents; Anti-Ulcer Agents; Carbonic Anhydrase Inhibitors; Drug Approval; Enzyme Inhibitors; Hypoglycemic Agents; Lansoprazole; Metformin; Omeprazole; Pregnadienes; Sulfonamides; Thiophenes; Trisaccharides; United States; United States Food and Drug Administration | 1996 |
Nonhealing gastric ulcer caused by chronic alendronate administration.
Topics: Abdominal Pain; Aged; Alendronate; Anti-Ulcer Agents; Bone Resorption; Drug Administration Schedule; Female; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Osteoporosis, Postmenopausal; Postprandial Period; Stomach Ulcer | 2002 |
Protective effect of melatonin and omeprazole against alendronat-induced gastric damage.
Topics: Administration, Oral; Alendronate; Animals; Anti-Ulcer Agents; Antioxidants; Fasting; Female; Gastric Acidity Determination; Gastrointestinal Diseases; Injections, Intraperitoneal; Male; Melatonin; Omeprazole; Rats | 2005 |
No increased bone formation around alendronate or omeprazole loaded bioactive bone cements in a femoral defect.
Topics: Alendronate; Animals; Bone Cements; Bone Density; Bone Density Conservation Agents; Enzyme Inhibitors; Female; Femur; Inflammation; Omeprazole; Osteogenesis; Rabbits; Time Factors; Tomography, X-Ray Computed | 2008 |
Osteogenic activity of locally applied small molecule drugs in a rat femur defect model.
Topics: Alendronate; Animals; Bone Density; Disease Models, Animal; Femur; Lovastatin; Male; Omeprazole; Organ Size; Osteogenesis; Rats; Rats, Sprague-Dawley; Wound Healing; X-Ray Microtomography | 2010 |
Discontinuation of unnecessary medications in older adults.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Ulcer Agents; Antihypertensive Agents; Assisted Living Facilities; Bone Density Conservation Agents; Case Management; Diabetes Mellitus; Drug Therapy; Evidence-Based Medicine; Guidelines as Topic; Hepatitis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lisinopril; Longevity; Male; Omeprazole; Osteoporosis; Palliative Care; Pharmacists; Precision Medicine; Simvastatin | 2011 |
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Interactions; Estrogens; Female; Femur; Omeprazole; Ovariectomy; Pantoprazole; Proton Pump Inhibitors; Rats; Rats, Wistar; Tibia | 2012 |